Thrombectomy Devices Market is Expected to Reach $1,389 Million by 2022, Globally - Allied Market Research

PORTLAND, Oregon, October 26, 2016 /PRNewswire/ --

A new report published by Allied Market Research, titled, "Thrombectomy Devices Market - Global Opportunity Analysis and Industry Forecast, 2014 - 2022, states that the global thrombectomy devices market was $913 million in 2015 and is expected to reach $1,389 million by 2022, growing at a CAGR of 5.9% from 2016 to 2022. Mechanical thrombectomy would continue to be the preferred technology throughout analysis period. North America dominated with around half of the market share in 2015 and is projected to maintain the lead throughout the forecast period.

     (Logo: http://photos.prnewswire.com/prnh/20140911/647229 )

Summary of the Thrombectomy Devices Market Report can be accessed on the website at https://www.alliedmarketresearch.com/thrombectomy-devices-market

High occurrences of acute myocardial infarction, peripheral artery disease, deep vein thrombosis, VTE (Venous Thromboembolism) and pulmonary embolism owing to the sedentary, and unhealthy lifestyle majorly drives the market growth. VTE is most common in adults (>60 years). In addition, better healthcare infrastructure and increase in demand for minimally-invasive treatments; rise in the geriatric population, which increases incidence of cardiovascular diseases; and technological advancements & innovations are the factors that nurture the growth of the thrombectomy devices market. Some of the restraints associated with the thrombectomy devices market are scarcity of trained professionals, lack of awareness, and the complicated use of devices.

Disposable thrombectomy devices segment generated highest revenue in 2015 and would continue to follow this trend throughout the analysis period.

Geographically, North America occupied a major market share in 2015, and is expected to continue leading during analysis period. This was attributed to the sedentary and unhealthy lifestyle of the current generation, demand of better healthcare infrastructure, and increase in demand for minimally-invasive treatments and incidence of cardiovascular diseases. However, Asia-Pacific followed by LAMEA are expected to be the fastest growing regions, owing to the presence of ample growth opportunities in terms of unmet medical needs for the treatment of thrombus.